Related Experiment Video
Updated: Jun 17, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer
Giulia Cursano1,2, Alberto Concardi1,2, Mariia Ivanova1
1Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.
This study found significant variability in TROP2 expression analysis across different immunohistochemistry assays for triple-negative breast cancer. Standardizing these assays is crucial for reliable TROP2 biomarker assessment.
Area of Science:
- Oncology
- Immunohistochemistry
- Biomarker Analysis
Background:
- Sacituzumab govitecan targets TROP2 in metastatic triple-negative breast cancer (TNBC).
- TROP2 expression, assessed by immunohistochemistry (IHC), correlates with improved outcomes but lacks standardized assays.
- This variability impacts the reliable clinical utility of TROP2 as a biomarker.
Purpose of the Study:
- To evaluate the consistency of TROP2 expression analysis across three different IHC assays.
- To assess the concordance of TROP2 quantification using the H-score method.
- To identify the need for standardized IHC protocols in TNBC TROP2 biomarker assessment.
Main Methods:
- Analyzed 26 TNBC samples using three distinct IHC assays (ENZO-ABS380-0100, Abcam SP295, Santa Cruz B9-sc-376746) on a Dako Omnis platform.
- Quantified TROP2 membrane expression using the H-score, categorizing results as low, intermediate, or high.
- Evaluated assay agreement using Cohen's κ and Gwet's AC2 statistics.
Main Results:
- Significant variability in TROP2 expression classification was observed across the three assays.
- Assays B and C showed substantial agreement (80.8% concordance, κ = 0.81), while overall concordance between all three assays was fair to moderate (AC2 = 0.35).
- Assay A demonstrated a broader range of TROP2 expression compared to assays B and C.
Conclusions:
- There are significant inter-assay variations in TROP2 detection, impacting its reliability as a biomarker in TNBC.
- TROP2 expression is heterogeneous and dynamic, necessitating methodological improvements in IHC testing.
- Standardized IHC protocols and quantitative scoring systems, potentially integrated with computational pathology, are needed to enhance TROP2's clinical utility.
Related Concept Videos
Higher Mental Functions of the Brain: Language
Language formation and comprehension take place in the dominant hemisphere. The dominant hemisphere is responsible for understanding the meaning of spoken, written, or sign language, as well as the ability to communicate. For most people, the left hemisphere is the dominant one. The right hemisphere, then, gives tone and emotional context to the...
Cerebral Hemispheres
Lateralization
Language and Cognition
Learning Disabilities
Dyslexia
Dyslexia is a...

